US 6858638B2
· Damour et al.
· 2005
[cited by applicant]
US 20090029970A1
· Takeshita
· 2009
[cited by applicant]
US 20220273662A1
· Oh et al.
· 2022
[cited by applicant]
US 20230257376A1
· Li et al.
· 2023
[cited by applicant]
US 20230312530A1
· Zhao et al.
· 2023
[cited by applicant]
WO WO2009023179A2
· 2009
[cited by applicant]
WO WO2009155209A1
· 2009
[cited by applicant]
WO WO2011050245A1
· 2011
[cited by applicant]
WO WO2012214200A1
· 2021
[cited by applicant]
WO WO2023139379A1
· 2023
[cited by applicant]
WO WO2023209692A1
· 2023
[cited by applicant]
Chowdhury et al. (Bioorganic & Medicinal Chemistry Letters. vol. 21, Issue 23, Dec. 1, 2011, pp. 7107-7112). (Year: 2011).
[cited by examiner]
Glyn et al (ChemRxiv. 2021; doi: 10.26434/chemrxiv.14402387.v1). (Year: 2021).
[cited by examiner]
Staiger, B. (“Pharmaceutical Dosage Forms: A Review.” (2017 first published; 2018 last updated). https://walrus.com/articles/pharmaceutical-dosage-forms-a-review). (Year: 2017).
[cited by examiner]
Sun et al. (Bioorganic & Medicinal Chemistry Letters; vol. 28, Issue 20, Nov. 1, 2018, pp. 3283-3289). (Year: 2018).
[cited by examiner]
Koch et al. (Pharmacology & Therapeutics. Volume 189, Sep. 2018, pp. 1-21). (Year: 2018).
[cited by examiner]
Bye et al. (Experimental Neurology 279, 86-95 (2016). https://doi.org/10.1016/j.expneurol.2016.02.012). (Year: 2016).
[cited by examiner]
Naseer et al. (Biomolecules. Oct. 11, 2022; 12(10):1457. doi: 10.3390/biom12101457. PMID: 36291666; PMCID: PMC9599474.) (Year: 2022).
[cited by examiner]
Chowdhury, Sarwat, et al. “Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).”
[cited by applicant]
Defert, Olivier, and Sandro Boland. “Rho kinase inhibitors: a patent review (2014-2016).”
[cited by applicant]
Duffy, Philip, et al. “Rho-associated kinase Ii (RockII) limits axonal growth after trauma within the adult mouse spinal cord.”
[cited by applicant]
Feng, Yangbo, et al. “Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.”
[cited by applicant]
Feng, Yangbo, and Philip V. LoGrasso. “Rho kinase inhibitors: a patent review (2012-2013).”
[cited by applicant]
Feng, Yangbo, et al. “Rho kinase (ROCK) inhibitors and their therapeutic potential.”
[cited by applicant]
Koch, Jan Christoph, et al. “ROCK inhibition in models of neurodegeneration and its potential for clinical translation.”
[cited by applicant]
Koch, Jan C., et al. “Compassionate use of the ROCK inhibitor fasudil in three patients with amyotrophic lateral sclerosis.”
[cited by applicant]
Li, Xiaohong, et al. “PRKX critically regulates endothelial cell proliferation, migration, and vascular-like structure formation.”
[cited by applicant]
Lingor, Paul, et al. “ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosi…
[cited by applicant]
Lograsso, Philip V., and Yangbo Feng. “Rho kinase (ROCK) inhibitors and their application to inflammatory disorders.”
[cited by applicant]
Moskal, Natalia, et al. “ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway.”
[cited by applicant]
Rikitake, Yoshiyuki, and James K. Liao. “ROCKs as therapeutic targets in cardiovascular diseases.”
[cited by applicant]
Roser, Anna-Elisa, Lars Tönges, and Paul Lingor. “Modulation of microglial activity by Rho-kinase (ROCK) inhibition as therapeutic strategy in Parkinson's disease and amyotrophic lateral sclerosis.”
[cited by applicant]
Sessions, E. Hampton, et al. “Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).”
[cited by applicant]
Tatenhorst, Lars, et al. “Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.”
[cited by applicant]
Wang, Qing, et al. “Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases.”
[cited by applicant]
Weber, Audrey J., and Jeremy H. Herskowitz. “Perspectives on ROCK2 as a Therapeutic Target for Alzheimer's Disease.”
[cited by applicant]
Yin, Yan, et al. “Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.”
[cited by applicant]
International search report and written opinion for PCT/US23/86402, 10 pages, mailed on May 23, 2024.
[cited by applicant]
U.S. Appl. No. 18/610,041, filed Mar. 19, 2024, Thomas Maxwell Kaiser.
[cited by applicant]